| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers E > Headlines for Exelixis, Inc. > News item |
Exelixis on track to file three NDAs and end year with $130 million
By Lisa Kerner
Charlotte, N.C., Oct. 13 - Exelixis, Inc. is on track to once again file three New Drug Applications with the Food and Drug Administration in one year, as it has in 2004 and 2005, president and chief executive officer George Scangos said Tuesday. The company has filed two NDAs so far this year.
"We have nine compounds in clinical development and we have another six compounds that will get into the clinic in the next year or so," Scangos said today at the 2006 Biotechnology Industry Organization Investor Forum in San Francisco.
Scangos, who said he expects the company's pipeline to continue to grow, outlined the progress of four compounds: XL647 and XL888, both with one of four studies ongoing and three to begin in the first-quarter 2007, XL 999 has six of six studies ongoing and XL784 is currently being studied in a double-blind placebo study.
"If we look at ourselves a year from now, we'll have multiple compounds in late-stage clinical trials," Scangos said.
"Some of them will be with our partner GlaxoSmithKline, some of them will be within Exelixis. We have another set of compounds coming forward; we anticipate new partnerships and we anticipate clinical data on a large fraction of that pipeline over the next 6 to 12 months."
Financially, Scangos said his company will revise its forecast for the third quarter.
"So far we have been successful at keeping ourselves financed," Scangos added. Exelixis will finish the year with more than $130 million, not including the $90 million the company recently financed.
Exelixis is a development-stage biotechnology company based in South San Francisco, Calif.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.